Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

  • End date
    Sep 30, 2024
  • participants needed
  • sponsor
    The First Affiliated Hospital with Nanjing Medical University
Updated on 12 March 2022
progressive disease
cancer chemotherapy
targeted therapy
lung carcinoma
squamous non-small cell lung cancer
non-squamous non-small cell lung cancer


A phase II study to assess the efficacy and safety of Fruquintinib Combined With Sintilimab and Chemotherapy as a first-line treatment in patients with unresectable or metastatic advanced Wild-type Genotype non-squamous Non-small Cell Lung Cancer.

Condition Carcinoma, Non-Small-Cell Lung
Treatment Fruquintinib,Sintilimab,Pemetrexed,Carboplatin
Clinical Study IdentifierNCT04956146
SponsorThe First Affiliated Hospital with Nanjing Medical University
Last Modified on12 March 2022


Yes No Not Sure

Inclusion Criteria

Voluntary provision of informed consent
Males or females aged 18-75
Histological or cytologically confirmed NSCLC, metastatic or non-resectable (stage IIIB-Ⅳ)
Not suitable for targeted therapy (patients with non-squamous NSCLC have no EGFR, ALK, gene mutation)
At least one lesion can be measured by imaging
Have not received systemic treatment in the past
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
Life expectancy ≥ 12 weeks
Female of childbearing age must have a negative pregnancy test (serum or urine) within 7 days before enrolment

Exclusion Criteria

Histological or cytologically confirmed small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC
Diagnosed with other malignant diseases other than NSCLC within 5 years
Have participated in other interventional clinical research treatments now or within 4 weeks
Have previously received multi-targeted kinase inhibitors therapy
Have active autoimmune diseases requiring systemic treatment within 2 years
Received systemic glucocorticoid therapy or immunosuppressive therapy within 2 weeks
Clinically uncontrollable pleural effusion/abdominal effusion
Vaccinated vaccines or attenuated vaccines within 4 weeks before the group
Pregnant or breastfeeding females
Other serious hazards to the safety of patients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note